Mustafa Khasraw

Summary

Affiliation: University of Sydney
Country: Australia

Publications

  1. doi request reprint Advances in the treatment of malignant gliomas
    Mustafa Khasraw
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Oncol Rep 12:26-33. 2010
  2. doi request reprint Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
    Mustafa Khasraw
    Department of Medical Oncology, Royal North Shore Hospital, Pacific Highway, St Leonards, New South Wales 2065, Australia
    J Clin Neurosci 16:854-5. 2009
  3. doi request reprint Management of advanced neuroendocrine tumors with hepatic metastasis
    Mustafa Khasraw
    Department of Medical Oncology, Royal North Shore Hospital, Sydney, St Leonards NSW, Australia
    J Clin Gastroenterol 43:838-47. 2009
  4. doi request reprint Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
    M Khasraw
    Department of Oncology, Royal North Shore Hospital, Australia
    Ann Oncol 21:1302-7. 2010
  5. doi request reprint Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours
    M Khasraw
    Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales 2065, Australia
    Intern Med J 40:453-8. 2010
  6. doi request reprint The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?
    Mustafa Khasraw
    Evelyn H Lauder Breast and Imaging Center, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Curr Oncol Rep 13:17-25. 2011
  7. doi request reprint Neurological complications of systemic cancer
    Mustafa Khasraw
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, USA
    Lancet Neurol 9:1214-27. 2010
  8. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013

Collaborators

Detail Information

Publications8

  1. doi request reprint Advances in the treatment of malignant gliomas
    Mustafa Khasraw
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Oncol Rep 12:26-33. 2010
    ..This review focuses on recent advances in the treatment malignant gliomas, especially antiangiogenic therapy...
  2. doi request reprint Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
    Mustafa Khasraw
    Department of Medical Oncology, Royal North Shore Hospital, Pacific Highway, St Leonards, New South Wales 2065, Australia
    J Clin Neurosci 16:854-5. 2009
    ..These patients have continued TMZ for 5 years, 7 years and 8 years respectively. So far they have had no serious side effects. We discuss these patients while raising the question of prolonged TMZ use...
  3. doi request reprint Management of advanced neuroendocrine tumors with hepatic metastasis
    Mustafa Khasraw
    Department of Medical Oncology, Royal North Shore Hospital, Sydney, St Leonards NSW, Australia
    J Clin Gastroenterol 43:838-47. 2009
    ..A variety of antiangiogenesis and growth factor-targeted agents have been evaluated, but to date, the results have failed to meet our expectations...
  4. doi request reprint Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
    M Khasraw
    Department of Oncology, Royal North Shore Hospital, Australia
    Ann Oncol 21:1302-7. 2010
    ..We studied the combination of PI-88, an inhibitor of angiogenesis and heparanase activity, and docetaxel in chemotherapy-naive CRPC...
  5. doi request reprint Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours
    M Khasraw
    Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales 2065, Australia
    Intern Med J 40:453-8. 2010
    ..Further investigation in prospective trials is warranted and the possibility for late responses might have implications for trial design...
  6. doi request reprint The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?
    Mustafa Khasraw
    Evelyn H Lauder Breast and Imaging Center, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Curr Oncol Rep 13:17-25. 2011
    ....
  7. doi request reprint Neurological complications of systemic cancer
    Mustafa Khasraw
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, USA
    Lancet Neurol 9:1214-27. 2010
    ..We focus on disorders that are difficult to diagnose, need neurological consultation, and for which effective treatments exist...
  8. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013
    ..In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)...